{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:47:17Z","timestamp":1793213237063,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00520-018-4381-0","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T04:29:19Z","timestamp":1533097759000},"page":"927-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients"],"prefix":"10.1007","volume":"27","author":[{"given":"Ana Lu\u00edsa","family":"de Castro Baccarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macilon Nonato","family":"Irene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"de Iracema Gomes Cubero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana Sales","family":"Luz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suelen Nastri","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renan","family":"Sordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Eduardo Silva","family":"M\u00f3z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Del Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"4381_CR1","doi-asserted-by":"publisher","unstructured":"Picard M, Castells MC (2014) Re-visiting hipersensitivity reactions to taxanes: a comprehensive review. Rev Allerg Immunol. \n                    https:\/\/doi.org\/10.1007\/s12016-014-8416-0","DOI":"10.1007\/s12016-014-8416-0"},{"issue":"5","key":"4381_CR2","first-page":"458","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss RB et al (1992) Hypersensitivity reactions. Semin Oncol 19(5):458\u2013477","journal-title":"Semin Oncol"},{"issue":"4","key":"4381_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaip.2014.04.010","volume":"2","author":"A Banerji","year":"2014","unstructured":"Banerji A et al (2014) Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2(4):428\u2013433","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"4381_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1006\/gyno.2001.6331","volume":"82","author":"JB Robinson","year":"2001","unstructured":"Robinson JB et al (2001) Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynaecologic malignancies. Gynecol Oncol 82(3):550\u2013558","journal-title":"Gynecol Oncol"},{"issue":"16","key":"4381_CR5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663\u20131671","journal-title":"N Engl J Med"},{"issue":"3","key":"4381_CR6","first-page":"179","volume":"5","author":"FA Greco","year":"1999","unstructured":"Greco FA et al (1999) One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am 5(3):179\u2013191","journal-title":"Cancer J Sci Am"},{"key":"4381_CR7","unstructured":"Tsavaris N et al. A simplified premedication protocol for one-hour paclitaxel infusion in various combinations. J Support Oncol 2005;3(1):77\u201381"},{"issue":"2","key":"4381_CR8","first-page":"46","volume":"11","author":"E Dewaele","year":"2017","unstructured":"Dewaele E et al (2017) Premedication strategy for paclitaxel, still an unsolved question after years. Belg J Med Oncol 11(2):46\u201355","journal-title":"Belg J Med Oncol"},{"key":"4381_CR9","unstructured":"Green MC et al. Rates of adverse events with low-dose dexamethasone (Dex) as premedication of weekly paclitaxel (Pac) utilized as adjuvant\/neoadjuvant therapy for operable breast cancer. Program and abstracts of the American Society of Clinical Oncology 2009 Breast Cancer Symposium; Abstract 307"},{"issue":"2\u20133","key":"4381_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000085618","volume":"51","author":"AS Braverman","year":"2005","unstructured":"Braverman AS et al (2005) Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. Chemotherapy 51(2\u20133):116\u2013119","journal-title":"Chemotherapy"},{"key":"4381_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1081\/CNV-120003535","volume":"20","author":"J Quock","year":"2002","unstructured":"Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D (2002) Premedication strategy for weekly paclitaxel. Cancer Investig 20:666\u2013672","journal-title":"Cancer Investig"},{"issue":"3","key":"4381_CR12","first-page":"283","volume":"24","author":"H Koppler","year":"2001","unstructured":"Koppler H et al (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24(3):283\u2013285 English, German","journal-title":"Onkologie"},{"issue":"5","key":"4381_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ et al (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12(5):601\u2013609","journal-title":"Oncologist"},{"issue":"7","key":"4381_CR14","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00520-014-2556-x","volume":"23","author":"MJ Berger","year":"2015","unstructured":"Berger MJ et al (2015) Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 23(7):2019\u20132024","journal-title":"Support Care Cancer"},{"key":"4381_CR15","unstructured":"National Cancer Institute (US). Division of cancer treatment and diagnosis. Common toxicity criteria (Computer Program). Version v4.03: June 14, 2010. NCI"},{"issue":"5","key":"4381_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"4381_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1026461310761","volume":"6","author":"M Klee","year":"1997","unstructured":"Klee M et al (1997) Quality of life of Danish women: population based norms for the EORTC QLQ-C30. Qual Life Res 6:27\u201334","journal-title":"Qual Life Res"},{"issue":"11","key":"4381_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1590\/S0100-720320140005081","volume":"36","author":"MD Ricci","year":"2014","unstructured":"Ricci MD et al (2014) Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer. Rev Bras Ginecol Obstet 36(11):503\u2013543","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"4","key":"4381_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.18203\/2319-2003.ijbcp20150369","volume":"4","author":"N Chauhan","year":"2015","unstructured":"Chauhan N et al (2015) Comparative study of quality of life in breast cancer patients receiving two different chemotherapy regimens using European Organization for Research and Treatment of Cancer Quality of Questionnaire-Core 30 questionnaire module for tolerability and safety. Int J Basic Clin Pharmacol 4(4):664\u2013672","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"11","key":"4381_CR20","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0959-8049(98)00167-1","volume":"34","author":"P Stone","year":"1998","unstructured":"Stone P et al (1998) Fatigue in patients with cancer. Eur J Cancer 34(11):1670","journal-title":"Eur J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4381-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T21:40:25Z","timestamp":1567028425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4381-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4381"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4381-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical trial was approved by the Institution\u2019s Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}